Stammdaten
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Unternehmen & Branche
| Name | Tempest Therapeutics, Inc. |
|---|---|
| Ticker | TPST |
| CIK | 0001544227 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 7,6 Mio. USD |
| Beta | -1,89 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -26,262,000 | -6.33 | 16,931,000 | 6,668,000 | |
| 2025-09-30 | 10-Q | -3,511,000 | -0.79 | 17,129,000 | 6,346,000 | |
| 2025-06-30 | 10-Q | -7,870,000 | -2.07 | 24,484,000 | 9,783,000 | |
| 2025-03-31 | 10-Q | -10,860,000 | -3.16 | 32,164,000 | 11,133,000 | |
| 2024-12-31 | 10-K | -41,843,000 | -19.50 | 41,488,000 | 19,126,000 | |
| 2024-09-30 | 10-Q | -10,556,000 | -5.32 | 33,836,000 | 11,457,000 | |
| 2024-06-30 | 10-Q | -9,570,000 | -5.52 | 42,169,000 | 16,939,000 | |
| 2024-03-31 | 10-Q | -7,904,000 | -4.62 | 44,378,000 | 20,632,000 | |
| 2023-12-31 | 10-K | -29,491,000 | -1.91 | 51,603,000 | 26,768,000 | |
| 2023-09-30 | 10-Q | -6,786,000 | -0.48 | 23,987,000 | -1,190,000 | |
| 2023-06-30 | 10-Q | -7,581,000 | -0.54 | 30,742,000 | 5,012,000 | |
| 2023-03-31 | 10-Q | -7,636,000 | -0.55 | 37,329,000 | 10,965,000 | |
| 2022-12-31 | 10-K | -35,709,000 | -3.09 | 46,089,000 | 18,111,000 | |
| 2022-09-30 | 10-Q | -8,947,000 | -0.66 | 63,171,000 | 26,773,000 | |
| 2022-06-30 | 10-Q | -9,168,000 | -0.79 | 71,351,000 | 34,932,000 | |
| 2022-03-31 | 10-Q | -8,491,000 | -1.18 | 66,953,000 | 29,357,000 | |
| 2021-12-31 | 10-K | -28,302,000 | -7.47 | 73,238,000 | 36,117,000 | |
| 2021-09-30 | 10-Q | -8,110,000 | -1.21 | 67,142,000 | -43,536,000 | |
| 2021-06-30 | 10-Q | -7,058,000 | -7.63 | 75,497,000 | 48,114,000 | |
| 2021-03-31 | 10-Q | -5,355,000 | -10.55 | 73,238,000 | -73,951,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.